Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

思路迪医药
3D Medicines

3D Medicines Inc.
思路迪医药股份有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1244)

VOLUNTARY ANNOUNCEMENT
Latest Progress in Collaboration Programs: Achievement of Pre-specified Number of Events in the Global Pivotal Phase 3 REGAL Trial for 3D189

This announcement is made by 3D Medicines Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors of the Company (the "**Board**") is pleased to announce the latest significant progress in its collaboration programs in respect of 3D189 (Galinpepimut-S, GPS) with SELLAS Life Sciences Group, Inc. ("**SELLAS**").

3D189 is the Company's second product nearing commercialisation, it is an investigational therapy for the treatment of acute myeloid leukemia (AML). It will be the world's first WT1 tumor vaccine, if approved. The Company acquired the exclusive development and commercialization rights of 3D189 in Greater China in 2020.

As of October 28, 2026, the pivotal Phase 3 REGAL trial evaluating GPS in patients with acute myeloid leukemia (AML) has reached the pre-specified 80th event (number of deaths), triggering the final analysis of the study.

The REGAL trial is an event-driven overall survival study, and with the occurrence of the 80th event, SELLAS will proceed with database lock, unblinding of the study data, and statistical analysis of the primary endpoint data. Upon completion of this analysis, Sellas will announce this quarter the preliminary topline primary endpoint results from the trial in accordance with the study's pre-specified statistical analysis plan (SAP).

The Company reminds investors that the results of clinical studies are uncertain, and subsequent links such as data statistical analysis, submission of clinical trial reports and drug registration and approval may be affected by various factors, which involves certain risks. The Company will timely disclose the follow-up progress of this clinical trial in accordance with the requirements of the Listing Rules and relevant laws and regulations. Investors are advised to invest prudently and pay attention to investment risks.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong, October 29, 2026

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Ms. ZHANG Wenhua, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.